Allokin-alfa, lyophilizate 1 mg 3 pcs

Pharmacotherapeutic group: antiviral, immunomodulatory agent

ATX code J05AX, L03A

Pharmacological properties

Pharmacodynamics

Alloferon is an oligopeptide. By the nature of its pharmacological action it is the most similar to interferon alfa. Alloferon is an effective inducer of endogenous interferon synthesis and activator of natural killer system, it is able to stimulate recognition and lysis of defective cells by cytotoxic lymphocytes. High effectiveness against infections caused by influenza A and B viruses, hepatitis B and C, herpes types 1 and 2 and human papilloma has been demonstrated in experiments. Alloferon has no general toxicity, allergenic properties, mutagenic and carcinogenic action, does not have embryotoxic effect and does not affect reproductive function.

Pharmacokinetics

It quickly penetrates into the blood, where it interacts with immunocompetent cells, after which determination of Alloferon concentration is difficult due to the close structural similarity of its metabolites with serum proteins. The increased concentration of interferon was noted 2 hours after drug administration and remained at a high level (2-2.5 times higher than the usual background level) for 6-8 hours, reaching the baseline values by the end of the day. Increased functional activity of natural killers was observed for 7 days after the drug administration.

Indications

Chronic papillomavirus infection caused by oncogenic human papillomaviruses, chronic recurrent herpes types 1 and 2, as part of complex therapy for the moderate (icteric) form of acute hepatitis B.

Pharmacological effect

Pharmacotherapeutic group: antiviral, immunomodulatory agent

ATX code J05AX, L03A

PHARMACOLOGICAL PROPERTIES

Pharmacodynamics

Alloferon is an oligopeptide. The nature of the pharmacological action is most similar to interferon alpha. Alloferon is an effective inducer of the synthesis of endogenous interferons and an activator of the natural killer system, capable of stimulating the recognition and lysis of defective cells by cytotoxic lymphocytes. Experiments have demonstrated high effectiveness against infections caused by influenza A and B viruses, hepatitis B and C, herpes types 1 and 2 and human papilloma. Alloferon does not have general toxicity, allergenic properties, mutagenic or carcinogenic effects, does not have embryotoxic effects and does not affect reproductive function.

Pharmacokinetics

It quickly penetrates into the blood, where it interacts with immunocompetent cells, after which determining the concentration of Alloferon is difficult due to the close structural similarity of its metabolites to blood serum proteins. An increase in interferon concentration was observed 2 hours after administration of the drug and remained at a high level (2-2.5 times higher than the usual background) for 6-8 hours, reaching the initial values ​​by the end of the day. Increased functional activity of natural killer cells was observed within 7 days after drug administration.

Special instructions

In monotherapy, Allokin-alpha is recommended for the treatment of human papillomavirus infection caused by oncogenic types of the virus, in the absence of clinical and subclinical lesions of the cervix and anogenital area.
As part of complex therapy – for the treatment of clinical and subclinical forms of lesions of the cervix and anogenital area by human papillomavirus infection caused by oncogenic types of the virus.
Treatment of chronic recurrent herpes types 1 and 2 is recommended to begin when the very first signs of the disease appear.
For hepatitis B – no later than the 7th day from the onset of jaundice.

Impact on the ability to drive a car and operate machinery
If dizziness occurs, you should refrain from driving or operating machinery.

Active ingredient

Histidyl-glycyl-valyl-seryl-glycyl-histidyl-glycyl-glutaminyl-histidyl-glycyl-valyl-histidyl-glycine

Composition

For 1 ampoule: Alloferon [Histidyl-glycyl-valyl-seryl-glycyl-histidyl-glycyl-glutaminyl-histidyl-glycyl-valyl-histidyl-glycine] 1.0 mg

Contraindications

Hypersensitivity, pregnancy and breastfeeding (stop during treatment), severe autoimmune diseases.

Children’s age.

Side Effects

In some cases, weakness, dizziness, and the formation of new rash elements (with herpetic infection) are possible.

Interaction

In the treatment of chronic recurrent genital herpes, it can be prescribed in combination with acyclovir and its derivatives (the drugs have different mechanisms of action and complement each other in the treatment of viral infection). In acute hepatitis B, the drug is prescribed against the background of generally accepted basic therapy.

No interaction with other drugs has been identified.

Overdose

To date, no cases of drug overdose have been identified.

Short product description

Please note: bonuses and promotional codes are not available for this product.

Storage conditions

Store in a place protected from light at a temperature of 2 to 8 °C.
Keep out of the reach of children.

Shelf life

2 years. Do not use after expiration date.

Manufacturer

Federal State Budgetary Institution RKNPK of the Ministry of Health of Russia, Russia